fC6MQX

Poster Presentations – Sunday, October 19, 3:30 pm - 7:00 pmP473. Deep Remission With Vedolizumab in Patients With UlcerativeColitis: Evaluating Various Combinations of Endoscopic and Patient-Reported OutcomesWilliam Sandborn, MD, FACG, Jean-Frederic Colombel, MD, PhD,Remo Panaccione, MD, Karen Lasch, MD, Serap Sankoh, PhD, BrihadAbhyankar, MBA, Division of Gastroenterology, University of CaliforniaSan Diego, La Jolla, CA, Icahn School of Medicine at Mount Sinai,New York, NY, Department of Medicine, University of Calgary, Calgary,AB, Canada, Takeda Pharmaceuticals International, Inc., Deerfield, IL,Takeda Pharmaceuticals International Co., Cambridge, MA, TakedaGlobal Research and Development Centre (Europe) Ltd., London,United KingdomP474. Vedolizumab Results in Durable Clinical Remission in Crohn’sDiseaseWilliam Sandborn, MD, FACG, Silvio Danese, MD, PhD, BrihadAbhyankar, MBA, Walter Reinisch, MD, PhD, Jing Xu, PhD, KarenLasch, MD, Catherine Milch, MD, Division of Gastroenterology,University of California San Diego, La Jolla, CA, IBD Center, IstitutoClinico Humanitas, Milan, Italy, Takeda Global Research andDevelopment Centre (Europe) Ltd., London, United Kingdom,Department of Internal Medicine III, Medical University of Vienna,Vienna, Austria, Takeda Pharmaceuticals International Co., Cambridge,MA, Takeda Pharmaceuticals International, Inc., Deerfield, ILP475. Assessment of Fecal Markers and Clinical Outcomes in PatientsWith Moderately to Severely Active Ulcerative Colitis: Results FromPURSUIT-SC InductionWilliam Sandborn, MD, Brian Feagan, MD, Colleen Marano, PhD,Richard Strauss, MD, Jewel Johanns, PhD, Hongyan Zhang, PhD,Jean-Frederic Colombel, MD, Walter Reinisch, MD, Peter Gibson, MD,Judith Collins, MD, Dino Tarabar, MD, Zbigniew Hebzda, MD, PaulRutgeerts, MD, University of California San Diego, La Jolla, CA, RobartsResearch Institute, London, ON, Canada, Janssen R&D, LLC, SpringHouse, PA, CHU, Lille, France, U für Innere Medizin III/McMasterUniversity, Vienna and Hamilton, Austria, Alfred Hospital, Melbourne,VIC, Australia, Oregon Health Sciences University, Portland, OR, MilitaryMedical Academy, Belgrade, Serbia, Klinika Chorob Wewnetrznych,Krakow, Poland, U Hospital, Gasthuisberg, Leuven, BelgiumP476. Predictors of Maintenance of Long-term Remission in Crohn’sDisease Patients Treated With Certolizumab Pegol: Multivariate andUnivariate Analyses From the PRECiSE 3 StudyWilliam Sandborn, MD, Stefan Schreiber, MD, Corey Siegel, MD,Gil Melmed, MD, Dermot McGovern, MD, Bosny Pierre-Louis, PhD,Gordana Kosutic, MD, Marshall Spearman, MD, University of CaliforniaSan Diego, La Jolla, CA, Christian-Albrechts University at Kiel, Kiel,Germany, Dartmouth-Hitchcock Medical Center, Lebanon, NH, Cedars-Sinai Medical Center, Los Angeles, CA, UCB Pharma, Raleigh, NCP477. Clinical Outcomes in Continuous Clinical Responders WithModerately to Severely Active Ulcerative Colitis: Sub-analyses From thePURSUIT-SC Maintenance StudyWilliam Sandborn, MD, Jean-Frederic Colombel, MD, Walter Reinisch,MD, Peter Gibson, MD, Brian Feagan, MD, Colleen Marano, PhD,Richard Strauss, MD, Jewel Johanns, PhD, Hongyan Zhang, PhD,Haoling Weng, MD, MHS, Ruji Yao, PhD, Dino Tarabar, MD, ZbigniewHebzda, MD, Paul Rutgeerts, MD, University of California San Diego,La Jolla, CA, Hôpital Claude Huriez, Lille, France, Universitätsklinikfür Innere Medizin III/McMaster U, Vienna/Hamilton, Austria, AlfredHospital, Melbourne, VIC, Australia, Robarts Research Institute,London, ON, Canada, Janssen R&D, LLC, Spring House, PA, MerckSharp and Dohme, Kenilworth, NJ, Military Medical Academy,Belgrade, Serbia, Klinika Chorob Wewnetrznych,Krakow, Krakow,Poland, University Hospital Gasthuisberg, Leuven, BelgiumP478. Serum Albumin as a Predictor of Long-term Response andRemission With Certolizumab Pegol for Crohn’s Disease: Results From7-Year Data From the PRECiSE 3 StudyWilliam Sandborn, MD, Finlay Macrae, MD, Ian Lawrance, MD, DavidSen, PhD, Sarah Abbas, MD, Kevin Douglas, MD, Gary Lichtenstein,MD, University of California San Diego, La Jolla, CA, Royal MelbourneHospital, Melbourne, VIC, Australia, University of Western Australia,Fremantle Hospital, WA, Australia, UCB Pharma, Raleigh, NC,University of Pennsylvania School of Medicine, Philadelphia, PAP479. Stratification of Crohn’s Disease Patients Using the Lemann Indexto Quantify Gut Damage: A 5 Year Prospective Study2014 ACG Governors Award for Excellence in Clinical Research2014 ACG Presidential Poster AwardBhavana Bhagya Rao, MD, Claudia Ramos Rivers, MD, Jean-FredericColombel, MD, PhD, Miguel Regueiro, MD, Jason Swoger, MD, MarcSchwartz, MD, Leonard Baidoo, MD, Jana Hashash, MD, Arthur Barrie,MD, PhD, Michael Dunn, MD, David Binion, MD, Medicine, Universityof Pittsburgh, Pittsburgh, PA, Icahn School of Medicine at Mount Sinai,New York, NYINFLAMMATORY BOWEL DISEASE -CLINICAL VIGNETTESP480. Crohn’s Flare Causes a CatastropheAnam Khan, MD, Yamini Natarajan, MD, Joseph Sellin, MD, FACG,Internal Medicine, Baylor College of Medicine, HoustonP481. Budd Chiari Syndrome Induced by Severe Ulcerative Colitis: ACase Report of Two Patients Without Thrombophilia2014 ACG Presidential Poster AwardAmar Mandalia, MD, Parit Mekaroonkamol, MD, Heba Iskandar, MD,MSc, Tanvi Dhere, MD, Emory University - Department of InternalMedicine, Atlanta, GA, Emory University - Division of Digestive Diseases,Atlanta, GAP482. Isolated Gastroduodenal Crohn’s DiseaseMatthew Sullivan, DO, Patrick Hickey, DO, Saba Ahmad, MD, JeffreyBrodsky, MD, Hiral Shah, MD, Ronald Bross, MD, Lehigh Valley HealthNetwork, Allentown, PAP483. Gastric Outlet Obstruction Caused by Crohn’s DiseaseVictor Velocci, MD, Mohammad Nasser, MD, Peter McCullough, MD,Internal Medicine, Providence Hospital, Southfield, MI, Baylor Heartand Vascular Institute, Dallas, TXP484. Crohn’s Disease Presenting as an Inflammatory Cecal Mass in anAsymptomatic PatientSvetlana Fridlyand, DO, David Wan, MD, Nassau University MedicalCenter, East Meadow, NY, New York-Presbyterian Hospital, New York,NYP485. Infliximab and Colchicine Therapy in the Treatment of SystemicSecondary Amyloidosis in Crohn’s DiseaseGeoffrey You, MD, William Ferges, MD, Kiron Das, MD, PhD,Department of Medicine, Rutgers Robert Wood Johnson MedicalSchool, New Brunswick, NJ, Division of Gastroenterology andHepatology, Department of Medicine, Rutgers Robert Wood JohnsonMedical School, New Brunswick, NJP486. Case Report: Atypical Presentation of Pyelonephritis in a Crohn’sDisease Patient on AdalimumabMohamad Houry, MD, Sara Wikstrom, MD, Angela Pham, MD, GeorgeWashington University Hospital, Washington, DCP487. Ménétrier’s Disease and Ulcerative Colitis: True, True andUnrelated?Bradley Anderson, MD, Seth Sweetser, MD, Mayo Clinic, Rochester,MNP488. An Abdominal Catastrophe in an Obstetric Patient: PerforatedCrohn’s DiseaseJessica Burgers, MD, John Leff, MD, Oscar Ruiz, MD, OhioHealthRiverside Methodist Hospital, Columbus, OHP489. Abdominal Actinomycosis Complicating Active Crohn’s Disease: ACase ReportAhmad Malli, MD, Guru Trikudanathan, MD, Courtney Ferch, MD,Ashish Malhotra, MD, University of Minnesota Medical Center,Minneapolis, MN, Minneapolis VA Medical Center, Minneapolis, MNP490. The Management of IBD With Biologics in the Third Trimester ofPregnancyAnish Mammen, MD, Burton Korelitz, MD, FACG, Lenox Hill Hospital,New York, NYFor more information on ACG 2014 and to register, visit www.acgmeetings.gi.org.60